RPG Life Sciences Limited has reported standalone financial results for the period ended December 31, 2023.
RPG Life Sciences Limited has reported Standalone financial results for the period ended September 30, 2023.
The government needs to set up a separate ministry for the pharma sector to encourage domestic producers and decrease Chinese imports, opined CEOs while participating in a discussion on the challenges being faced by the sector.
Shares of RPG Life Sciences continued at their northward movement, hitting a fresh record high of Rs 751.80, up 8 per cent on the BSE in intra-day trade on Tuesday. So far in the month of September, the stock of the pharmaceutical company has zoomed 51 per cent on expectation of a promising outlook for the domestic formulation industry.
With the collapse of transport network in the country, RPG Life Sciences is reaching out directly to critically-ill patients via its portal to deliver medicines.
RPG Life Sciences inks pact to acquire Sun Pharma`s 7 brands
Most recently the use of ‘integration interruption’ capability of chromatography data systems has been identified as a means of data manipulation. In addition, some firms have gone to extremes in physically blocking the FDA’s access to areas which they have a right to inspect.
Sun Pharmaceutical IndustriesBSE 0.01 % on Friday completed the divestment of its seven prescription brands in India to RPG Life Sciences. This has been done after receiving approval of the Competition Commission of India and completion of all the necessary formalities for closure of the transaction, Sun Pharmaceutical Industries said in a filing to BSE.
The U.S. Food and Drug Administration opened the door on Tuesday to a change in its blood donor deferral recommendations, which currently prohibit donations from gay men for a year following their last sexual encounter in order to reduce the risk of transmitting HIV, the virus that causes AIDS.
RPG Life Sciences has signed an agreement with Sun Pharmaceutical to acquire seven prescription brands primarily in respiratory and urology segments and entered collaboration with Biophore, US, for the development of niche products. The company also entered into business transfer agreement in May 2016 with Intas Pharmaceuticals Ltd for sale of Biotech Business Unit, as going concern on a slump sale basis for a total consideration of Rs.24.87 crore.